ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
-0,25%
S&P 500
5.469,30
0,39%
US Dollar vs BRL
5,4517
-0,01%
Bitcoin
61.464,66
-0,56%
Brent Oil
84,775
0,70%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Notícias

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TVTX
DataHoraFonteTítuloCódigoCompanhia
14/06/202417:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TVTXTravere Therapeutics Inc
11/06/202418:00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
13/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
10/05/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/05/202417:30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
08/05/202417:30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
06/05/202417:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
06/05/202417:01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202408:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202404:00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
11/03/202408:05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
23/02/202409:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202404:00PR Newswire (Canada)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202410:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202418:01GlobeNewswire Inc.Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
14/02/202416:35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TVTXTravere Therapeutics Inc
08/02/202418:30GlobeNewswire Inc.Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
01/02/202423:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
01/02/202418:30GlobeNewswire Inc.Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:TVTXTravere Therapeutics Inc
25/01/202418:05GlobeNewswire Inc.Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian NationsNASDAQ:TVTXTravere Therapeutics Inc
08/01/202409:00GlobeNewswire Inc.Travere Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:TVTXTravere Therapeutics Inc
02/01/202418:30GlobeNewswire Inc.Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
14/12/202309:30GlobeNewswire Inc.Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)NASDAQ:TVTXTravere Therapeutics Inc
04/12/202319:14Dow Jones NewsTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNASDAQ:TVTXTravere Therapeutics Inc
04/12/202318:05GlobeNewswire Inc.Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGSNASDAQ:TVTXTravere Therapeutics Inc
21/11/202318:30GlobeNewswire Inc.Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TVTXTravere Therapeutics Inc
07/11/202318:01GlobeNewswire Inc.Travere Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TVTX

Seu Histórico Recente

TSXV
GTEC
GTEC
EU
IWENS
ISHARES WENS INAV
BIT
S28205
Societe Generale Effekten
LSE
OL24
Citi Fun 30
LSE
SILF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados